The Week In... Pharma (02-06/12)
  • Posted on: 06/12/2019
  • Category: Industry

The Week In... Pharma (02-06/12)

Celltrion Healthcare receive EU approval for their Remsima drug, Astellas purchases a gene therapy company for $3 billion, the ABPI recruit internally for their new CEO, and could a ‘liquid health check’ predict disease risk?

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

ABPI looks internally for new CEO, naming Richard Torbett

The new chief executive of the Association of the British Pharmaceutical Industry (ABPI) will be Dr Richard Torbett following the retirement of Mike Thompson at the end of the year.

Celltrion bags EU approval for Remsima SC off back of new data

Celltrion has revealed data from its Remsima SC (infliximab) trials, evaluating a subcutaneous (SC) biosimilar version of the treatment in patients with Chron’s disease, ulcerative colitis and rheumatoid arthritis.

Astellas buys gene therapy company for $3bn

Astellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of approximately $3 billion, adding a new focus area to its drug discovery efforts.

Pharma in 2019: Has uncertainty led to pharma innovation and change?

As the year draws to a close, has uncertainty led to pharma innovation and change in 2019? Have we been in a Brexit-related stasis? Or have pharma and healthcare been moving forward regardless of the stalemate in Westminster? We look back at January’s predictions, policy and commercial developments over the year.

Study suggests ‘liquid health check’ could help predict disease risk

A new study has found that proteins in blood could potentially help provide a comprehensive “liquid health check” in the future, assessing our health and predicting the likelihood that we will we will develop a range of diseases.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.